N-ACETYL CYSTEINE IN SCHIZOPHRENIA RESISTANT TO CLOZAPINE: A DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED TRIAL TARGETING NEGATIVE SYMPTOMS
Grant number: 1098442 | Funding period: 2016 - 2019
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
Related publications (2)
Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review
Caitlin OB Yolland, Andrea Phillipou, David J Castle, Erica Neill, Matthew E Hughes, Cherrie Galletly, Zoe M Smith, Paul S Francis, Olivia M Dean, Jerome Sarris, Dan Siskind, Anthony WF Harris, Susan L Rossell
OBJECTIVES: Schizophrenia is a debilitating psychiatric illness associated with positive and negative symptoms as well as signific..
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms
Susan L Rossell, Paul S Francis, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia Dean, Dennis Liu, Denny Meyer, Erica Neill, Andrea Phillipou, Jerome Sarris, David J Castle